These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37925144)

  • 41. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
    Abdo M; Watz H; Veith V; Kirsten AM; Biller H; Pedersen F; von Mutius E; Kopp MV; Hansen G; Waschki B; Rabe KF; Trinkmann F; Bahmer T
    Respir Res; 2020 Oct; 21(1):278. PubMed ID: 33087134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.
    Cates CJ; Karner C
    Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007313. PubMed ID: 23633340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical remission with biologic therapies in severe asthma: a matter of definition.
    ; McDowell PJ; McDowell R; Busby J; Eastwood MC; Patel PH; Jackson DJ; Mansur A; Patel M; Burhan H; Doe S; Chaudhuri R; Gore R; Dodd JW; Subramanian D; Brown T; Heaney LG
    Eur Respir J; 2024 Jun; 63(6):. PubMed ID: 38901893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences.
    Bakakos A; Rovina N; Loukides S; Bakakos P
    Expert Opin Biol Ther; 2022 Jul; 22(7):855-870. PubMed ID: 35712995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world super-response to biologics in severe asthma: A French monocentric retrospective cohort study.
    Valéry S; Habib-Maillard S; Roche N
    Respir Med Res; 2023 Nov; 84():101055. PubMed ID: 37897876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
    Anderson WC; Szefler SJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term safety, durability of response, cessation and switching of biologics.
    Mohan A; Qiu AY; Lugogo N
    Curr Opin Pulm Med; 2024 May; 30(3):303-312. PubMed ID: 38426355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic Assessment for Difficult and Severe Asthma Improves Outcomes and Halves Oral Corticosteroid Burden Independent of Monoclonal Biologic Use.
    Denton E; Lee J; Tay T; Radhakrishna N; Hore-Lacy F; Mackay A; Hoy R; Dabscheck E; O'Hehir RE; Hew M
    J Allergy Clin Immunol Pract; 2020 May; 8(5):1616-1624. PubMed ID: 31954193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.
    Adir Y; Humbert M; Saliba W
    J Allergy Clin Immunol; 2021 Aug; 148(2):361-367.e13. PubMed ID: 34144110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistence of asthma biologic use in a US claims database.
    Maddux JT; Inselman JW; Jeffery MM; Lam RW; Shah ND; Rank MA
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):648-654. PubMed ID: 33971361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Airway autoimmunity, asthma exacerbations, and response to biologics.
    Venegas Garrido C; Mukherjee M; Bhalla A; Nair P
    Clin Exp Allergy; 2022 Dec; 52(12):1365-1378. PubMed ID: 35993511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Asthma Remission Obtained with Biologics in Real Life: Patients' Prevalence and Characteristics.
    Sposato B; Bianchi F; Ricci A; Scalese M
    J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37374008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.
    Maglio A; Vitale C; Pelaia C; D'Amato M; Ciampo L; Sferra E; Molino A; Pelaia G; Vatrella A
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study.
    Quarato CMI; Tondo P; Lacedonia D; Soccio P; Fuso P; Sabato E; Hoxhallari A; Foschino Barbaro MP; Scioscia G
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202298
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy of biologic therapy on airway hyperresponsiveness in asthma.
    Chan R; Lipworth B
    Ann Allergy Asthma Immunol; 2023 Jul; 131(1):37-41. PubMed ID: 36841374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-World Effectiveness of IL-5/5Ra Targeted Biologics in Severe Eosinophilic Asthma With Comorbid Bronchiectasis.
    Bendien SA; Kroes JA; van Hal LHG; Braunstahl GJ; Broeders MEAC; Oud KTM; Patberg KW; Smeenk FWJM; van Veen IHPAA; Weersink EJM; Fieten KB; Hashimoto S; van Veen A; Sont JK; van Huisstede A; van de Ven MJT; Langeveld B; Maitland-van der Zee AH; Ten Brinke A;
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2724-2731.e2. PubMed ID: 37295671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both.
    Pfeffer PE; Ali N; Murray R; Ulrik C; Tran TN; Maspero J; Peters M; Christoff GC; Sadatsafavi M; Torres-Duque CA; Altraja A; Lehtimäki L; Papadopoulos NG; Salvi S; Costello RW; Cushen B; Heffler E; Iwanaga T; Al-Ahmad M; Larenas-Linnemann D; Kuna P; Fonseca JA; Al-Lehebi R; Rhee CK; Perez-de-Llano L; Perng Steve DW; Mahboub B; Wang E; Goh C; Lyu J; Newell A; Alacqua M; Belevskiy AS; Bhutani M; Bjermer L; Bjornsdottir U; Bourdin A; Bulow AV; Busby J; Canonica GW; Cosio BG; Dorscheid DR; Muñoz-Esquerre M; FitzGerald JM; Gil EG; Gibson PG; Heaney LG; Hew M; Hilberg O; Hoyte F; Jackson DJ; Koh MS; Ko HB; Lee JH; Lehmann S; Chaves Loureiro C; Lúðvíksdóttir D; Menzies-Gow AN; Mitchell P; Papaioannou AI; Popov TA; Porsbjerg CM; Salameh L; Sirena C; Taillé C; Taube C; Tohda Y; Wechsler ME; Price DB
    Allergy; 2023 Jul; 78(7):1934-1948. PubMed ID: 36929509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.